Transcenta Holding Limited (6628.HK)
HKD 0.6
(0.0%)
HKD 0.6
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -486.52 Million CNY | -14.39% |
| 2022 | -389.31 Million CNY | 77.44% |
| 2021 | -1.72 Billion CNY | -462.22% |
| 2020 | -306.93 Million CNY | 15.78% |
| 2019 | -364.45 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -68.62 Million CNY | 40.45% |
| 2024 Q2 | -68.62 Million CNY | 0.0% |
| 2023 Q1 | -128.02 Million CNY | -18.43% |
| 2023 FY | -445.33 Million CNY | -14.39% |
| 2023 Q4 | -115.23 Million CNY | 0.0% |
| 2023 Q3 | -115.23 Million HKD | 9.99% |
| 2023 Q2 | -128.02 Million CNY | 0.0% |
| 2022 Q2 | -113.06 Million CNY | 0.0% |
| 2022 Q1 | -113.06 Million CNY | 17.57% |
| 2022 FY | -389.31 Million CNY | 77.44% |
| 2022 Q4 | -108.1 Million CNY | 0.0% |
| 2022 Q3 | -108.1 Million CNY | 4.39% |
| 2021 Q3 | -137.16 Million CNY | 85.2% |
| 2021 Q4 | -137.16 Million CNY | 0.0% |
| 2021 Q2 | -926.81 Million CNY | -1041.23% |
| 2021 Q1 | -81.21 Million CNY | 29.54% |
| 2021 FY | -1.72 Billion CNY | -462.22% |
| 2020 Q1 | -21.58 Million CNY | 0.0% |
| 2020 FY | -306.93 Million CNY | 15.78% |
| 2020 Q4 | -115.26 Million CNY | 0.0% |
| 2020 Q3 | -115.26 Million CNY | -34.36% |
| 2020 Q2 | -85.78 Million CNY | -297.53% |
| 2019 FY | -364.45 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 817.921% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 154.181% |